(Q35685864)

English

The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia

scientific article published on March 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Roehrborn CG

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2004

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

93 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

21-26

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Health-related quality of life associated with lower urinary tract symptoms in four countries.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Association of health-related quality of life and benign prostatic enlargement.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

The progression of benign prostatic hyperplasia: examining the evidence and determining the risk

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04636.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2003.04636.X

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35685864&oldid=1635348822"